Professional Documents
Culture Documents
Home
2. ELEVIT®Pronatal
ELEVIT®Pronatal
ELEVIT®Pronatal is a pregnancy multivitamin and mineral supplement that has been specially
formulated to help meet the increased nutritional needs of women who are trying to conceive,
pregnant and breastfeeding.
One per day | Chain store and pharmacy | Store below 25˚C
Deciding to start or extend a family marks the beginning of an exciting and momentous journey for
a couple. A journey for which preparation is key.
ELEVIT®Pronatal is a pregnancy multivitamin and mineral supplement that has been specially
formulated to help meet the increased nutritional needs of women in preparation for pregnancy,
during pregnancy and throughout lactation.
Key vitamins and minerals that are essential to support baby’s healthy
development include:
• Folic Acid – ELEVIT®Pronatal contains 800μg folic acid
• Iron – ELEVIT®Pronatal contains 60mg of elemental iron
The key benefits behind the essential ingredients6 include:
Folic Acid:
During the first few weeks of pregnancy, before most women find out that they are pregnant, the
neural tube has already developed or closed. The neural tube forms the baby’s brain and spinal cord,
which is essential to the central nervous system. A woman’s nutritional folate status can play an
important role in the formation of the neural tube.22 Folic acid, the supplemental form of folate, is
clinically proven to reduce the risk of birth defects.6
Iron:
Iron demand increases during pregnancy and infancy. Iron supplementation will be necessary to
help prevent iron deficiency conditions12, especially for pregnant women and children 6-24 months
of age.
Dosage
ELEVIT®Pronatal is a small once daily tablet that can be taken any time of the day, with a glass of
water. (In case of morning sickness, it is recommended that the tablet is taken at noon, or if
necessary in the evening.) It is best to take ELEVIT®Pronatal from planning for pregnancy, during
pregnancy, throughout lactation.11
Special Precautions11
• The recommended dosage should not be exceeded and the drug should not be taken together
with other drugs and/or food containing Vitamin A and/or Vitamin D in order to avoid
overdosage of these vitamins.
• Concurrent administration of antacids with oral iron preparations may decrease iron
absorption. Antacids and oral iron preparations should be administered as far apart as
possible.
• Oral administration of iron preparations inhibits absorption of tetracyclines from the
gastrointestinal tract and vice versa, leading to decreased serum concentrations of both the
antibiotic and iron. If simultaneous administration of the drugs is necessary, patients should
receive the tetracycline 2 hours after or 2 hours before oral iron administration.
Contra-indications11
• ELEVIT®Pronatal should not be used by patients with pre-existing hyper-vitaminosis A
and/or D or with impaired renal function, iron accumulation and iron utilization disorders,
hypercalcemia or hypercalciuria, and hypersensitivity to any ingredient of the product.
Undesirable effects11
• ELEVIT®Pronatal is well to tolerated. in rare cases gastrointestinal disturbances (e.g.
constipation) may occur, but these generally do not necessitate withdrawal of therapy.
• ELEVIT®Pronatal contains iron, which may lead to a back colouring of the stool. This does
not have any clinical relevance.
Speak to your doctor about taking Elevit if you have any pre-existing medical conditions.
References:
• 4. Otten JJ, Hellwig JP, Meyers LD. (2006) Dietary Reference Intakes The Essential Guide
to Nutrient Requirements (p532-535) Washington D.C.,: National Academy of Sciences.
• 6. Czeizel (2004) Int J Med Sci 1(1) 50-61
• 8. Czeizel (1992) Arch Gynecol Obstet; 251:181-185
• 11. ELEVIT®Pronatal Package Insert 02/2013
• 12. J. Stoltzfus, R. and L. Dreyfuss, M. (n.d.). Guidelines for the Use of Iron Supplements to
Prevent and Treat Iron Deficiency Anemia. p.11.
• 22. Blencowe H., Cousens S., Modell B. & Lawn J. (2010). Folic acid to reduce neonatal
mortality from neural tube disorders. International Journal of Epidemiology
*Internal calculations based on IMS R4B database MAT November 2014